Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$66.53 +1.37 (+2.10%)

As of 03:59 PM Eastern

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 12 Analyst Ratings

Sell
2

Hold
5

Buy
5

Based on 12 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 2 have given a sell rating, 5 have given a hold rating, and 5 have given a buy rating for NVO.

Consensus Price Target

$135.00
102.92% Upside

According to the 12 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $135.00. The highest price target for NVO is $160.00, while the lowest price target for NVO is $64.00. The average price target represents a forecasted upside of 102.92% from the current price of $66.53.

Get the Latest News and Ratings for NVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors.

NVO Analyst Ratings Over Time

Type	Current Forecast 4/30/24 to 4/30/25	1 Month Ago 3/31/24 to 3/31/25	3 Months Ago 1/31/24 to 1/30/25	1 Year Ago 5/1/23 to 4/30/24
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)
Hold	5 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	2 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$135.00	$145.25	$145.25	$133.60
Forecasted Upside	102.92% Upside	108.75% Upside	70.23% Upside	4.15% Upside
Consensus Rating	Hold	Moderate Buy	Buy	Moderate Buy

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novo Nordisk A/S Stock vs. The Competition

Type	Novo Nordisk A/S	Medical Companies	S&P 500
Consensus Rating Score	2.25	2.82	2.54
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	102.92% Upside	3,228.63% Upside	19.72% Upside
News Sentiment Rating	Positive News See Recent NVO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/25/2025	Dbs Bank 0 of 5 stars	N. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sell
4/17/2025	Guggenheim 2 of 5 stars	S. Fernandez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/17/2025	BMO Capital Markets 4 of 5 stars	Evan David Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$105.00 ➝ $64.00	+1.78%
4/15/2025	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Parkes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy ➝ Underperform
3/13/2025	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Evans Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
3/3/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/12/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight
1/8/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Walton Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Buy
1/6/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Kapadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
11/6/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $160.00	+49.39%
Get the Latest News and Ratings for NVO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.
6/10/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$125.00 ➝ $160.00	+13.09%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$156.00	+17.58%
12/4/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$105.00 ➝ $115.00	+14.19%
8/11/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:04 AM ET.

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 23, 2025. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

Novo Nordisk A/S
Bull Case

Here are some ways that investors could benefit from investing in Novo Nordisk:

The current stock price is around $61, reflecting a recent increase, which may indicate positive market sentiment towards the company.
Recent earnings reports show that Novo Nordisk has consistently exceeded earnings expectations, with a reported EPS of $0.91, surpassing the consensus estimate.
The company has a strong return on equity of 84.68%, suggesting effective management and profitability, which can be attractive to investors looking for solid financial performance.
Institutional interest is growing, with several funds significantly increasing their stakes in Novo Nordisk, indicating confidence in the company's future prospects.
With a market capitalization of approximately $275 billion, Novo Nordisk is positioned as a major player in the pharmaceutical industry, which can provide stability and growth potential for investors.

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

The stock has experienced significant volatility, with a 52-week high of $148.15 and a low of $57.00, which may concern risk-averse investors.
Despite recent gains, the stock's price-to-earnings (P/E) ratio of around 18.63 may suggest that it is overvalued compared to industry peers, potentially limiting future upside.
There is a high level of competition in the pharmaceutical sector, which could impact Novo Nordisk's market share and profitability in the long term.
The company's debt-to-equity ratio of 0.62 indicates a moderate level of debt, which could pose risks if market conditions change or if interest rates rise.
Recent market trends show a shift towards alternative treatments, which could affect demand for Novo Nordisk's products, particularly in a rapidly evolving healthcare landscape.

NVO Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $135.00, with a high forecast of $160.00 and a low forecast of $64.00.
: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
: According to analysts, Novo Nordisk A/S's stock has a predicted upside of 102.92% based on their 12-month stock forecasts.
: Over the previous 90 days, Novo Nordisk A/S's stock had 3 downgrades and 1 upgrade by analysts.
: Novo Nordisk A/S has been rated by research analysts at BMO Capital Markets, BNP Paribas, Dbs Bank, Guggenheim, Kepler Capital Markets, Morgan Stanley, and Stifel Nicolaus in the past 90 days.
: Analysts like Novo Nordisk A/S less than other "medical" companies. The consensus rating for Novo Nordisk A/S is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:NVO) was last updated on 4/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Stock Forecast & Price Target